At the 2023 scientific meeting of the American College of Cardiology with the World Congress of Cardiology (4-6 March 2023, New Orleans, USA), clinicians discussed latest cardiovascular research including the potential of triglyceride as a predictor of chronic kidney disease, REDUCE-IT results showing the benefits of icosapent ethyl after acute coronary syndrome, ENTRIGUE data on pegozafermin in severe hypertriglyceridaemia, preclinical findings on ANGPTL3 gene editing, the relative importance of cholesterol and inflammation in residual CV risk, and the value of measuring apoB.
Reportage by Jenny Bryan
Read the reports:
- Triglycerides linked to CKD risk
- Icosapent ethyl reduces ischaemic events after ACS
- Pegozafermin reduces triglyceride when added to lipid modifying therapy
- Preclinical data support potential efficacy of ANGPTL3 gene editing
- PROMINENT, REDUCE-IT and STRENGTH analysis shows need to address both lipids and inflammation
- Why measure apoB?